Is Biogen (BIIB) Fairly Valued On FDA Approval Of Its New Leqembi Autoinjector?

Simply Wall St.

Jul 14

Eisai and Biogen (BIIB) have received U.S. FDA approval for LEQEMBI IQLIK, a once weekly subcutaneous autoinjector initiation dose for early Alzheimer’s. This enables at home treatment and offers an ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2651178903"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651178903\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651178903?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-14 14:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651178903","market":"nz","top_or_hot":-1,"title":"Is Biogen (BIIB) Fairly Valued On FDA Approval Of Its New Leqembi Autoinjector?","media":"Simply Wall St.","content":"<div>\n<p>Eisai and Biogen (BIIB) have received U.S. FDA approval for LEQEMBI IQLIK, a once weekly subcutaneous autoinjector initiation dose for early Alzheimer’s. This enables at home treatment and offers an ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/is-biogen-biib-fairly-valued-on-fda-approval-of-its-new-leqe\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Biogen (BIIB) Fairly Valued On FDA Approval Of Its New Leqembi Autoinjector?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Biogen (BIIB) Fairly Valued On FDA Approval Of Its New Leqembi Autoinjector?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-14 14:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/is-biogen-biib-fairly-valued-on-fda-approval-of-its-new-leqe><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eisai and Biogen (BIIB) have received U.S. FDA approval for LEQEMBI IQLIK, a once weekly subcutaneous autoinjector initiation dose for early Alzheimer’s. This enables at home treatment and offers an ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/is-biogen-biib-fairly-valued-on-fda-approval-of-its-new-leqe\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/is-biogen-biib-fairly-valued-on-fda-approval-of-its-new-leqe","article_id":"2651178903","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/is-biogen-biib-fairly-valued-on-fda-approval-of-its-new-leqe","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2651178903","pubTimestamp":1784010448,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Eisai and Biogen (BIIB) have received U.S. FDA approval for LEQEMBI IQLIK, a once weekly subcutaneous autoinjector initiation dose for early Alzheimer’s. This enables at home treatment and offers an alternative to intravenous infusions.\nSee our latest analysis for Biogen.\nBiogen’s share price has recently picked up, with a 1-day share price return of 4.96% and a 90-day share price return of 16.80%. The 1-year total shareholder return of 57.04% contrasts with weaker 3 and 5 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BMED":"iShares Health Innovation Active ETF","BK4532":"文艺复兴科技持仓","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BIIB":"渤健公司","LABU":"三倍做多标普生物-Direxion","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD"},"translate_title":"百健（BIIB）对其新型Leqembi自动注射器的FDA批准是否公平？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PBE":0.6,"BMED":0.6,"BIIB":1.5,"LABU":1.5},"content_text":"Eisai and Biogen (BIIB) have received U.S. FDA approval for LEQEMBI IQLIK, a once weekly subcutaneous autoinjector initiation dose for early Alzheimer’s. This enables at home treatment and offers an alternative to intravenous infusions. See our latest analysis for Biogen. Biogen’s share price has recently picked up, with a 1-day share price return of 4.96% and a 90-day share price return of 16.80%. The 1-year total shareholder return of 57.04% contrasts with weaker 3 and 5 year total shareholder returns, suggesting momentum has strengthened only in the more recent period. If this Alzheimer’s progress has your attention, it could be a good moment to look across the wider healthcare technology space using our screener for 40 healthcare AI stocks Biogen’s recent share price jump sits at the crossroads of changing expectations and the underlying Alzheimer’s franchise story. To see which side is doing more of the work, it helps to line up the current valuation next. AdvertisementMost Popular Narrative: 4.7% Undervalued The most followed valuation narrative currently places Biogen’s fair value at about $219, modestly above the last close of $209.03 and framing the latest Alzheimer’s news within a slightly supportive valuation gap.  Broad international rollout and expanding reimbursement for SKYCLARYS and ZURZUVAE, particularly in rare diseases and underpenetrated markets, leverages growing global healthcare spending and improvements in medical infrastructure worldwide, increasing access and boosting long-term topline growth.  Read the complete narrative. Curious what underpins that fair value for Biogen? The narrative leans on steady revenue expansion, rising profit margins, and a future earnings multiple that assumes meaningful earnings growth. The full story ties those inputs directly to specific product launches and long term forecasts. Result: Fair Value of $219.27 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Biogen’s story still leans heavily on a small group of new launches, and rising biosimilar and pricing pressure could challenge the current Alzheimer’s driven optimism. Find out about the key risks to this Biogen narrative. Another View: Biogen Through the P/E Lens While the current fair value narrative suggests Biogen is modestly undervalued, the P/E picture is less forgiving. The stock trades on about 22.5x earnings, above both the US Biotechs average of 17.4x and peers at 18.8x, although close to its fair ratio of 23.5x. This mix of a premium relative to the sector and alignment with the fair ratio points to limited room for error in the Biogen story, especially if earnings or drug launches fall short of expectations. For investors comparing price and fundamentals, how comfortable does that valuation buffer really feel today? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:BIIB P/E Ratio as at Jul 2026Next Steps With sentiment around Biogen looking more optimistic but not one sided, it makes sense to review the underlying data yourself and move quickly to form a view based on the balance of risks and rewards. To see that balance set out clearly, take a closer look at the 2 key rewards and 1 important warning sign Looking for more ideas beyond Biogen? If Biogen has sharpened your focus on healthcare, do not stop there. Widen your watchlist with other stocks that fit clear, disciplined criteria.  Spot potential bargains early by scanning for companies that combine quality fundamentals with attractive pricing using the 46 high quality undervalued stocks Build a sturdier core to your portfolio by filtering for companies with stronger financial footing through the solid balance sheet and fundamentals stocks screener (47 results) Hunt for underfollowed opportunities by checking a screener containing 20 high quality undiscovered gems before the crowd catches on   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Biogen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}